Skip to main content
SpringerLink
Log in

Jurkat-Derived (J-Lat, J1.1, and Jurkat E4) and CEM-Derived T Cell Lines (8E5 and ACH-2) as Models of Reversible Proviral Latency

  • Protocol
  • First Online:
HIV Reservoirs

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2407))

Abstract

The introduction of combination antiretroviral therapy (cART) has switched HIV-1 infection from a lethal disease to a chronic one. Indeed, cART is a lifelong treatment since its interruption is always followed by a rapid rebound of viremia from both cellular and anatomical viral reservoirs where the integrated HIV-1 provirus remains transcriptionally silent or maintains low-levels of viral replication, thereby preventing HIV-1 eradication. As therapeutic approach, the “shock and kill” strategy has emerged with the main objective to reactivate HIV-1 transcription from latency by using latency reversing agents (LRAs) prior to kill the reactivated infected cells by improving host immune responses. In this context, the development of tools such as HIV-1 latently infected cell lines have drastically increased our knowledge about HIV-1 latency and how to counteract this highly heterogeneous phenomenon. In this chapter, we will describe several chronically HIV-1 infected T-lymphocytic cell lines as useful surrogate models to study reversible HIV-1 proviral latency in CD4+ T cells in vitro before approaching more complex and expensive models.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Dutilleul A, Rodari A, Van Lint C (2020) Depicting HIV-1 transcriptional mechanisms: a summary of what we know. Viruses 12:1385

    Article  CAS  PubMed Central  Google Scholar 

  2. Abner E, Jordan A (2019) HIV ‘shock and kill’ therapy: in need of revision. Antivir Res 166:19–34

    Article  CAS  PubMed  Google Scholar 

  3. Moranguinho I, Valente ST (2020) Block-and-lock: new horizons for a cure for HIV-1. Viruses 12:1443

    Article  CAS  PubMed Central  Google Scholar 

  4. Vansant G, Bruggemans A, Janssens J, Debyser Z (2020) Block-and-lock strategies to cure HIV infection. Viruses 12:84

    Article  CAS  PubMed Central  Google Scholar 

  5. Folks T et al (1985) Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U S A 82:4539–4543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Telwatte S et al (2019) Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency. Retrovirology 16:32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Folks TM et al (1986) Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med 164:280–290

    Article  CAS  PubMed  Google Scholar 

  8. Lightfoote MM et al (1986) Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol 60:771–775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Deichmann M, Bentz M, Haas R (1997) Ultra-sensitive FISH is a useful tool for studying chronic HIV-1 infection. J Virol Methods 65:19–25

    Article  CAS  PubMed  Google Scholar 

  10. Jackson JB et al (1993) Establishment of a quality assurance program for human immunodeficiency virus type 1 DNA polymerase chain reaction assays by the AIDS Clinical Trials Group. ACTG PCR Working Group, and the ACTG PCR Virology Laboratories. J Clin Microbiol 31:3123–3128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bourinbaiar AS, Ajuang-Simbiri K (1996) Simple procedure for estimating the efficiency of PCR. Mol Biotechnol 6:87–89

    Article  CAS  PubMed  Google Scholar 

  12. Busby E et al (2017) Instability of 8E5 calibration standard revealed by digital PCR risks inaccurate quantification of HIV DNA in clinical samples by qPCR. Sci Rep 7:1209

    Article  PubMed  PubMed Central  Google Scholar 

  13. Wilburn KM et al (2016) Heterogeneous loss of HIV transcription and proviral DNA from 8E5/LAV lymphoblastic leukemia cells revealed by RNA FISH:FLOW analyses. Retrovirology 13:55

    Article  PubMed  PubMed Central  Google Scholar 

  14. Clouse KA et al (1989) Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 142:431–438

    CAS  PubMed  Google Scholar 

  15. Folks TM et al (1989) Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A 86:2365–2368

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gimble JM et al (1988) Activation of the human immunodeficiency virus long terminal repeat by herpes simplex virus type 1 is associated with induction of a nuclear factor that binds to the NF-kappa B/core enhancer sequence. J Virol 62:4104–4112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Poli G et al (1990) Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A 87:782–785

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Biswas P et al (1995) Cross-linking of CD30 induces HIV expression in chronically infected T cells. Immunity 2:587–596

    Article  CAS  PubMed  Google Scholar 

  19. Takahashi Y et al (2001) OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection. J Virol 75:6748–6757

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Stanley SK, Bressler PB, Poli G, Fauci AS (1990) Heat shock induction of HIV production from chronically infected promonocytic and T cell lines. J Immunol 145:1120–1126

    CAS  PubMed  Google Scholar 

  21. Shankaran P, Vlkova L, Liskova J, Melkova Z (2011) Heme arginate potentiates latent HIV-1 reactivation while inhibiting the acute infection. Antivir Res 92:434–446

    Article  CAS  PubMed  Google Scholar 

  22. Thierry S et al (2007) High-mobility group box 1 protein induces HIV-1 expression from persistently infected cells. AIDS 21:283–292

    Article  CAS  PubMed  Google Scholar 

  23. Scheller C et al (2004) CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem 279:21897–21902

    Article  CAS  PubMed  Google Scholar 

  24. Papp B, Byrn RA (1995) Stimulation of HIV expression by intracellular calcium pump inhibition. J Biol Chem 270:10278–10283

    Article  CAS  PubMed  Google Scholar 

  25. Savarino A et al (2009) ‘Shock and kill’ effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 6:52

    Article  PubMed  PubMed Central  Google Scholar 

  26. Gunst JD et al (2019) Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation. J Virus Erad 5:133–137

    Article  PubMed  PubMed Central  Google Scholar 

  27. Laughlin MA, Chang GY, Oakes JW, Gonzalez-Scarano F, Pomerantz RJ (1995) Sodium butyrate stimulation of HIV-1 gene expression: a novel mechanism of induction independent of NF-kappa B. J Acquir Immune Defic Syndr Hum Retrovirol 9:332–339

    Article  CAS  PubMed  Google Scholar 

  28. Palmisano I et al (2012) Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci U S A 109:E2284–E2293

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Perez VL et al (1991) An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. J. Immunol 147:3145–3148

    CAS  PubMed  Google Scholar 

  30. Symons J et al (2017) HIV integration sites in latently infected cell lines: evidence of ongoing replication. Retrovirology 14:2

    Article  PubMed  PubMed Central  Google Scholar 

  31. Iwase SC et al (2019) HIV-1 DNA-capture-seq is a useful tool for the comprehensive characterization of HIV-1 provirus. Sci Rep 9:12326

    Article  PubMed  PubMed Central  Google Scholar 

  32. Okutomi T, Minakawa S, Hirota R, Katagiri K, Morikawa Y (2020) HIV reactivation in latently infected cells with Virological synapse-like cell contact. Viruses 12:417

    Article  PubMed Central  Google Scholar 

  33. Jordan A, Bisgrove D, Verdin E (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22:1868–1877

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Emiliani S et al (1996) A point mutation in the HIV-1 tat responsive element is associated with postintegration latency. Proc Natl Acad Sci U S A 93:6377–6381

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Emiliani S et al (1998) Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol 72:1666–1670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Antoni BA, Rabson AB, Kinter A, Bodkin M, Poli G (1994) NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line. Virology 202:684–694

    Article  CAS  PubMed  Google Scholar 

  37. Gaynor R (1992) Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS 6:347–363

    Article  CAS  PubMed  Google Scholar 

  38. Bachu M et al (2012) Multiple NF-κB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. J Biol Chem 287:44714–44735

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Pearson R et al (2008) Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol 82:12291–12303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Bosch V, Pawlita M (1990) Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site. J Virol 64:2337–2344

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Han Y et al (2004) Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 78:6122–6133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Spivak AM, Planelles V (2018) Novel latency reversal agents for HIV-1 cure. Annu Rev Med 69:421–436

    Article  CAS  PubMed  Google Scholar 

  43. Yukl SA et al (2018) HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med 10:eaap9927

    Article  PubMed  PubMed Central  Google Scholar 

  44. Vermeire J et al (2012) Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, Lenti- and Retroviral vectors. PLoS One 7:e50859

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

CVL acknowledges funding from the Belgian National Fund for Scientific Research (FRS-FNRS, Belgium), the European Union′s Horizon 2020 research and innovation programme (grant agreement No 691119-EU4HIVCURE-H2020-MSCA-RISE-2015), the “Fondation Roi Baudouin”, the NEAT (European AIDSTreatment Network) program, the “Fondation Roi Baudouin”, the Internationale Brachet Stiftung (IBS), ViiVHealthcare, the Walloon Region (Fonds de Maturation), “Les Amis des Instituts Pasteur á Bruxelles, asbl.”, andthe University of Brussels (ULB - Action de Recherche Concertée (ARC) grant) related to her work on HIVlatency. The laboratory of CVL is part of the ULB-Cancer Research Centre (U-CRC). AR is a postdoctoral fellow(ULB ARC program). CVL is “Directeur de Recherches” of the F.R.S-FNRS.

Author information

Authors and Affiliations

  1. Service of Molecular Virology, Department of Molecular Biology (DBM), Université Libre de Bruxelles (ULB), Gosselies, Belgium

    Anthony Rodari & Carine Van Lint

  2. Viral Pathogenesis Group, San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy

    Guido Poli

Authors
  1. Anthony Rodari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guido Poli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carine Van Lint
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carine Van Lint .

Editor information

Editors and Affiliations

  1. School of Medicine and Human Immuno-Virology (H.I.V.) Group, San Raffaele University and Scientific Institute, Milano, Italy

    Guido Poli

  2. Viral Pathogenesis and Biosafety Group, San Raffaele Scientific Institute, Milano, Italy

    Elisa Vicenzi

  3. Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Fabio Romerio

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Rodari, A., Poli, G., Van Lint, C. (2022). Jurkat-Derived (J-Lat, J1.1, and Jurkat E4) and CEM-Derived T Cell Lines (8E5 and ACH-2) as Models of Reversible Proviral Latency. In: Poli, G., Vicenzi, E., Romerio, F. (eds) HIV Reservoirs. Methods in Molecular Biology, vol 2407. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1871-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-1871-4_1

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-1870-7

  • Online ISBN: 978-1-0716-1871-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation